EU label for nilotinib now includes info on stopping therapy



CML cells
Image by Difu Wu
The European Commission has approved the inclusion of treatment-free remission (TFR) data in the European Union (EU) product information for nilotinib (Tasigna®). TFR is the ability to maintain molecular response after stopping tyrosine kinase inhibitor (TKI) therapy in patients with Ph+ chronic myeloid leukemia in chronic phase (CML-CP). Nilotinib... [Read Article]

Dasatinib potentially a new SOC for children with CML-CP, study author suggests



Child with cancer
Photo by Bill Branson
The largest ongoing and prospective trial of pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP), according to the best knowledge of the investigators, has found dasatinib to be safe and effective as first- or second-line therapy for these children. Patients refractory to or intolerant of imatinib... [Read Article]

Single-cell analysis reveals TKI-resistant CML stem cells



CML cells
Image by Difu Wu
Researchers say they’ve developed a technique for single-cell analysis that has revealed a population of treatment-resistant stem cells in patients with chronic myeloid leukemia (CML). “It is increasingly recognized that tumors contain a variety of different cell types, including so-called cancer stem cells, that drive the growth... [Read Article]

Proteins may be therapeutic targets for TKI-resistant CML, ALL



Micrograph showing TKI-
resistant CML in a mouse
Photo courtesy of
Cincinnati Children’s
Hospital Medical Center
Researchers say they have identified 2 signaling proteins that enable resistance to tyrosine kinase inhibitors (TKIs) and could be therapeutic targets for acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). The team found that by... [Read Article]

Imatinib is safe, effective long-term, team says



Imatinib tablet cut
with a pill splitter
Photo by Patrick Pelletier
Long-term follow-up of patients treated with imatinib suggests the drug can remain effective beyond 10 years and does not confer “unacceptable” cumulative toxicity, according to researchers. The group evaluated data on patients who had newly diagnosed, chronic-phase chronic myeloid leukemia (CML) when they... [Read Article]